Pharma News, 2024

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers ...

An Eli Lilly executive has said the company will “build a new way of doing science” as part of its £279m ($363m) pledge to boost the UK’s life science sector.  A memorandum of...

NEW YORK - Bright Minds Biosciences Inc., a biotechnology company specializing in CNS disorder treatments, has announced positive preclinical results for its drug candidate BMB-201. The substance, des...

Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the Company will highlight advances from across...

AstraZeneca PLC on Monday said that its antibody drug conjugate Enhertu won another approval in China. The Cambridge, England-based pharmaceutical company said that the National Medical Products Admin...

A promising vaccine candidate for Rift Valley fever (RVF) has been advanced into a phase 2 trial in Kenya, the first time that a shot has reached this stage of development in a country where t...

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that it has entered into a definitive agreement to s...

Sanofi has announced negotiations with Clayton Dubilier & Rice (CD&R), a US-based investment company, regarding the potential sale of a 50% controlling stake in its consumer healthcare bus...

Dizal, a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the Center for Drug Evaluation (CDE) of China&...

This approval marks the first and only anti-tissue factor pathway inhibitor approved in the US for the treatment hemophilia A or B, and the first approved hemophilia treatment to be administered via a...

In a year that has seen an approval and a raft of readouts for metabolic dysfunction-associated steatohepatitis (MASH), Gilead has decided to walk away from a $785 million biobucks deal in the...

AUS Food and Drug Administration (FDA) advisory committee (AdCom) has voted in support of Stealth BioTherapeutics’ first-line Barth syndrome drug, despite a trial studying the drug n...